文献速递血栓与止血白血病造血干细胞移植与细胞治疗

冻干血小板是出血性血小板减少血液肿瘤患者的潜在替代方案

Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies.
PubMed 文献 · Am J Hematol · 2021-12-23

本研究为开放标签1期试验,在三个剂量组共24例出血伴血小板减少的血液肿瘤患者中评估单次输注同种异体冻干血小板(Thrombosomes)的安全性与早期疗效信号。未报告剂量限制性毒性,WHO出血评分在基线活动性出血部位中63%改善、37%稳定,24小时后50%患者血小板计数出现临床显著升高。Thrombosomes可能成为治疗出血的常规血小板替代选择,2期试验正在进行中。

要点

  • 冻干血小板(Thrombosomes)为海藻糖稳定、O型冻干血小板,保质期3年,可库存、快速复溶且不受受者血型限制。
  • 1期试验中24例出血性血小板减少血液肿瘤患者接受单次冻干血小板输注,未报告剂量限制性毒性。
  • 基线活动性出血部位中63%改善、37%稳定;24小时后50%患者血小板计数临床显著升高。

核心结论

  • 冻干血小板(Thrombosomes)在出血性血小板减少血液肿瘤患者中显示出安全性及潜在早期疗效信号,可能成为常规血小板输注的替代选择。

研究设计与样本

  • 开放标签1期研究,单次输注同种异体Thrombosomes,设三个剂量水平、三个队列,每队列8例,共24例伴有血小板减少和出血的血液肿瘤患者。

主要发现

  • 未报告剂量限制性毒性(DLT)。
  • 中位年龄59岁(范围24-71岁)。
  • 大多数患者为AML(58%)或ALL(29%),其次为MDS(8%)和骨髓增殖性肿瘤(4%)。
  • 基线时22例患者共27个部位存在活动性出血,至第6天WHO出血评分改善17处(63%)、稳定10处(37%)。
  • 输注后24小时,12例患者(50%)血小板计数出现临床显著升高。

关键数值与推荐

  • Thrombosomes为海藻糖稳定的冻干O型血小板,保质期3年,可库存、快速复溶,且不受受者血型限制输注。

临床怎么用

  • 作者认为Thrombosomes可能成为治疗出血的常规血小板替代选择;一项在类似患者人群中开展的2期临床试验正在进行中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombosomes are trehalose-stabilized, freeze-dried group O platelets with a 3-year shelf life. They can be stockpiled, rapidly reconstituted, and infused regardless of the recipient's blood type. Thrombosomes thus represent a potential alternative platelet transfusion strategy. The present study assessed the safety and potential early signals of efficacy of Thrombosomes in bleeding thrombocytopenic patients. We performed an open-label, phase 1 study of single doses of allogeneic Thrombosomes at three dose levels in three cohorts, each consisting of eight patients who had hematologic malignancies, thrombocytopenia, and bleeding. Adverse events, dose-limiting toxicities (DLTs), World Health Organization (WHO) bleeding scores, and hematology values were assessed. No DLTs were reported. The median age was 59 years (24-71). Most patients had AML (58%) or ALL (29%), followed by MDS (8%) and myeloproliferative neoplasm (4%). The WHO scores of 22 patients who were actively bleeding at a total of 27 sites at baseline either improved (n = 17 [63%]) or stabilized (n = 10 [37%]) through day 6. Twenty-four hours after infusion, 12 patients (50%) had a clinically significant platelet count increase. Of eight patients who received no platelet transfusions for 6 days after Thrombosomes infusion, 5 had a clinically significant increase in platelet count of ≥5000 platelets/μL and 2 had platelet count normalization. Thrombosomes doses up to 3.78 × 108 particles/kg demonstrated safety in 24 bleeding, thrombocytopenic patients with hematological malignancies. Thrombosomes may represent an alternative to conventional platelets to treat bleeding. A phase 2 clinical trial in a similar patient population is underway.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ohanian M, Cancelas JA, Davenport R, et al. Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies. Am J Hematol. 2021. PMID: 34748664. doi:10.1002/ajh.26403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。